Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
KING OF PRUSSIA, Pa., February 09, 2009/PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with Cardiovascular Research Foundation.
Presentation Number: 2515-749 Abstract Title: Assessment of the pharmacokinetic and pharmacodynamic effects of intravenous clopidogrel in humans Time: Monday, Mar 30, 2009, 9:30 AM -10:30 AM Topic: Pharmacotherapy - Interventional Aspects Authors: Daniel Cushing, Raymond Lipicky, Peter Kowey, Christopher Cannon, Michael Adams, Warren Cooper, Gerold Mosher, Prism Pharmaceuticals
"We are very pleased to present the first data in humans of an IV formulation of clopidogrel at this most prestigious cardiology scientific session," said Dr. Warren D. Cooper, President and CEO of Prism. "PM103 is Prism's second acute care cardiovascular product that is being developed through our accelerated model, which focuses on bringing novel and improved formulations of existing compounds to the market."
PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX(R) (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyDex Pharmaceuticals, Inc. as an alternative dosage form to oral PLAVIX for use in the acute care setting.
Prism Pharmaceuticals, based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. The product portfolio strategy is focused on recognizing unfulfilled opportunities in existing compounds that address current unmet medical needs with a specific focus on medication safety in the hospital environment. Recently, Prism received FDA approval for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV.
CONTACT: Mariesa Kemble of Sam Brown Inc., +1-608-850-4745,, for Prism Pharmaceuticals email@example.com
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2009